Q-omics provides the consensus-scored NUDT19P2 profile across patient tissues and cancer cell-line models. NUDT19P2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, NUDT19P2 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, NUDT19P2 RNA expression shows 5,899 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, THCA, and STAD as cancer lineages where NUDT19P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUDT19P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUDT19P2 survival associations across molecular data types. NUDT19P2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUDT19P2 RNA expression–survival associations across cancer types. High NUDT19P2 expression shows unfavorable associations in LUSC, UCS, UVM, GBM, THCA and BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for NUDT19P2 RNA expression.
This table summarizes NUDT19P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for NUDT19P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUDT19P2 shows lower tumor expression in THCA. The THCA box plot shows higher NUDT19P2 RNA expression in normal versus tumor tissue (log2 FC = −0.011, t-test p = .034).
This table shows molecular features associated with NUDT19P2 in patient tissues and cancer cell lines. In patient samples, NUDT19P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
